explore -WSS

explore

author：knowledge 2025-08-12 09:10:36 - browse：666

US Capitol - SOTU — Lawmakers in Congress have decided to punt efforts to reform how PBMs operate. BRENDAN SMIALOWSKI/AFP/Getty Images

WASHINGTON — Congress has abandoned its attempt to reform how pharmacy middlemen operate in an upcoming package to fund the federal government, 11 lobbyists and sources following the talks told STAT.

It’s a missed opportunity to pass one of the health care priorities that has attracted the most bipartisan interest and activity this Congress, though lawmakers could revive the negotiations on the issues in the future.

Reforming how pharmacy benefit managers operate has been a top lobbying priority for the pharmaceutical industry since Democrats passed a major package aimed at lowering the costs of medicines in 2022. Pharma and PBMs have taken up a very public battle on the airwaves.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Medicare must police algorithms in Medicare Advantage, Dems say

explore

WSS

Medicare proceeds with plan to claw back hospital funds

The health care issue Democrats can’t solve: hospital reform

HPV vaccine, cervical cancer study delivers historic results

Head of FDA's diagnostics center, who led through Covid, retires

Kidney transplant patients stopped immunosuppressants in trial

Dog Aging Project founders on what lies ahead after losing funding

focus

explore

entertainment

Jerome Adams on the need for new antivirals for Covid

To bolster infectious disease surveillance, genomics powerhouses team up

Medical leaders decry Supreme Court decision on affirmative action

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Novavax promises a turnaround & Lilly roils the obesity market

There's an unseen cost to disruptive road

George Santos makes 1st court appearance after pleading not guilty to 13 counts

What is microchimerism and how does it affect maternal health?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Future doctors need a strong humanities education

leisure time

How to convince healthy people to buy insurance

Medicare proceeds with plan to claw back hospital funds

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Maisha Meds is a PBM, but don't call it that

Key Senate panel to consider PBM, drug pricing reform package

HPV vaccine, cervical cancer study delivers historic results

focus

entertainment

explore

focus